Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity

Neoplasia

Volumn 8, Issue 2, 2006, Pages 125-135

  Liu, Yuying ^a   Zhang, Weihe ^a   Niu, Ting ^b   Cheung, Lawrence H ^a   Munshi, Anupama ^a   Meyn Jr , Raymond E ^a   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Granzyme B; Immunotoxin; Melanoma; Single chain Fv antibody

Indexed keywords

CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANZYME B; MATRIGEL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SODIUM CHLORIDE; VINCRISTINE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL TRANSPORT; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR XENOGRAFT;

EID: 33646434791     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05556     Document Type: Article

References (54)

1. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, and Khayat D (2002). Metastatic melanoma: chemotherapy. Semin Oncol 29, 427-445.
2. Glinsky GV and Glinsky VV (1996). Apoptosis and metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 101, 43-51.
3. Glinsky GV, Glinsky VV, Ivanova AB, and Hueser CJ (1997). Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 115, 185-193.
4. Awada A, Cardoso F, Atalay G, Giuliani R, Mano M, and Piccart MJ (2003). The pipeline of new anticancer agents for breast cancer treatment in 2003. Crit Rev Oncol Hematol 48, 45-63.
5. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, and Pehamberger H (2000). Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
6. Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z, Kerbel RS, and Ben David Y (2004). Radiation resistance of human melanoma analyzed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene 23, 30-38.
7. Rockmann H and Schadendorf D (2003). Drug resistance in human melanoma: mechanisms and therapeutic opportunities. Onkologie 26, 581-587.
8. Soengas MS and Lowe SW (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3151.
9. Kantor RR, Ng AK, Giacomini P, and Ferrone S (1982). Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens. Hybridoma 1, 473-482.
10. Kantor RR, Albino AP, Ng AK, and Ferrone S (1986). Biosynthesis and intracellular processing of four human melanoma associated antigens. Cancer Res 46, 5223-5228.
11. Macey DJ, Denardo SJ, Denardo GL, Goodnight JK, and Unger MW (1988). Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am J Physiol Imaging 3, 1-6.
12. Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, and Bartholomew R (1991). A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3, 6-13.
13. 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother 39, 397-400.
14. Mujoo K, Cheung L, Murray JL, and Rosenblum MG (1995). Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40, 339-345.
15. Rosenblum MG, Cheung L, Mujoo K, and Murray JL (1995). An antimelanoma immunotoxin containing recombinant human tumor necrosis melanoma factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol Immunother 40, 322-328.
16. Liu Y, Cheung LH, Marks JW, and Rosenblum MG (2004). Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer 108, 549-557.
17. Rosenblum MG, Cheung LH, Liu Y, and Marks JW III (2003). Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 63, 3995-4002.
18. Liu Y, Cheung LH, Hittelman WN, and Rosenblum MG (2003). Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2, 1341-1350.
19. Rosenblum MG, Cheung L, Murray JL, and Bartholomew R (1991). Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun 3, 21-27.
20. Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, and Murray JL (1996). Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunol Immunother 42, 115-121.
21. Rosenblum MG, Marks JW, and Cheung LH (1999). Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 44, 343-348.
22. Smyth MJ and Trapani JA (1995). Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 16, 202-206.
23. Yagita H, Nakata M, Kawasaki A, Shinkai Y, and Okumura K (1992). Role of perforin in lymphocyte-mediated cytolysis. Adv Immunol 51, 215-242.
24. Shi L, Kraut RP, Aebersold R, and Greenberg AH (1992). A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 175, 553-566.
25. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, and Dixit VM (1996). The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 271, 16443-16446.
26. Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, Browne KA, and Trapani JA (2000). Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 192, 1403-1414.
27. Trapani JA, Browne KA, Smyth MJ, and Jans DA (1996). Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem 271, 4127-4133.
28. Osborne CK, Hobbs K, and Clark GM (1985). Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45, 584-590.
29. Simstein R, Burow M, Parker A, Weldon C, and Beckman B (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 228, 995-1003.
30. Rubio N, Espana L, Fernandez Y, Blanco J, and Sierra A (2001). Metastatic behavior of human breast carcinomas overexpressing the Bcl-x(L) gene: a role in dormancy and organospecificity. Lab Invest 81, 725-734.
31. + cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63, 483-488.
32. Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, and Chadban SJ (2003). Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 76, 1015-1022.
33. Humbert M, Devergne O, Cerrina J, Rain B, Simonneau G, Dartevelle P, Duroux P, Galanaud P, and Emilie D (1992). Activation of macrophages and cytotoxic cells during cytomegalovirus pneumonia complicating lung transplantations. Am Rev Respir Dis 145, 1178-1184.
34. MacDonald G, Shi L, Vande VC, Lieberman J, and Greenberg AH (1999). Mitochondria-dependent and -independent regulation of Granzyme B-induced apoptosis. J Exp Med 189, 131-144.
35. Spaeny-Dekking EH, Hanna WL, Wolbink AM, Wever PC, Kummer AJ, Swaak AJ, Middeldorp JM, Huisman HG, Froelich CJ, and Hack CE (1998). Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol 160, 3610-3616.
36. Smyth MJ, O'Connor MD, and Trapani JA (1996). Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. J Leukoc Biol 60, 555-562.
37. Smyth MJ, Browne KA, Thia KY, Apostolidis VA, Kershaw MH, and Trapani JA (1994). Hypothesis: cytotoxic lymphocyte granule serine proteases activate target cell endonucleases to trigger apoptosis. Clin Exp Pharmacol Physiol 21, 67-70.
38. Clement MV, Haddad P, Soulie A, Legros-Maida S, Guillet J, Cesar E, and Sasportes M (1990). Involvement of granzyme B and perforin gene expression in the lytic potential of human natural killer cells. Res Immunol 141, 477-489.
39. Wowk ME and Trapani JA (2004). Cytotoxic activity of the lymphocyte toxin granzyme B. Microbes Infect 6, 752-758.
40. Liu Y, Cheung LH, Thorpe P, and Rosenblum MG (2003). Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells. Mol Cancer Ther 2, 949-959.
41. Classen CF, Falk CS, Friesen C, Fulda S, Herr I, and Debatin KM (2003). Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression. Haematologica 88, 509-521.
42. Volm M and Koomagi R (1999). The implications of proliferation and apoptosis for lung cancer metastasis. Oncol Rep 6, 373-376.
43. Mustika R, Budiyanto A, Nishigori C, Ichihashi M, and Ueda M (2005). Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res ment 18, 59-62.
44. Mujoo K, Cheung L, Murray JL, and Rosenblum MG (1995). Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40, 339-345.
45. Schafer J, Bachtler J, Engling A, Little JB, Weber KJ, and Wenz F (2002). Suppression of apoptosis and clonogenic survival in irradiated human lymphoblasts with different TP53 status. Radiat Res 158, 699-706.
46. Uchida H, Shinoura N, Kitayama J,Watanabe T, Nagawa H, and Hamada H (2002). Caspase-8 gene transduction augments radiation-induced apoptosis in DLD-1 cells. Biochem Biophys Res Commun 292, 347-354.
47. Rocha S, Soengas MS, Lowe SW, Glanzmann C, Fabbro D, Winterhalter K, Bodis S, and Pruschy M (2000). Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway. Cell Growth Differ 11, 491-499.
48. Belka C, Heinrich V, Marini P, Faltin H, Schulze-Osthoff K, Bamberg M, and Budach W (1999). Ionizing radiation and the activation of caspase-8 in highly apoptosis-sensitive lymphoma cells. Int J Radiat Biol 75, 1257-1264.
49. Prpic ML, Kastelan M, Gruber F, Laskarin G, Sotosek V, Strbo N, Zamolo G, Zauhar G, and Rukavina D (2004). Perforin expression in peripheral blood lymphocytes and skin-infiltrating cells in patients with lichen planus. Br J Dermatol 151, 433-439.
50. Rieux-Laucat F, Le Deist F, and De Saint BG (2005). Autoimmune lymphoproliferative syndrome and perforin. N Engl J Med 352, 306-307.
51. Kreitman RJ (1999). Immunotoxins in cancer therapy. Curr Opin Immunol 11, 570-578.
52. McGrath MS, Rosenblum MG, Philips MR, and Scheinberg DA (2003). Immunotoxin resistance in multidrug resistant cells. Cancer Res 63, 72-79.
53. Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z, Yu CJ, Peng WD, Wen WH, Wang CJ, et al. (2004). Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 279, 21343-21348.
54. Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, Lilie H, and Jenne DE (2004). Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett 562, 87-92.